JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis

American Journal of Hematology

Volumn 86, Issue 6, 2011, Pages 526-528

  De Stefano, Valerio ^a   Rossi, Elena ^a   Za, Tommaso ^a   Ciminello, Angela ^a   Betti, Silvia ^a   Luzzi, Claudia ^a   Leone, Giuseppe ^a   Chiusolo, Patrizia ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTERY THROMBOSIS; FEMALE; GENE MUTATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTHEMIA; THROMBOPHILIA; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; CEREBRAL VEINS; CEREBROVASCULAR CIRCULATION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; RETROSPECTIVE STUDIES; SPLANCHNIC CIRCULATION; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; YOUNG ADULT;

EID: 79956134236     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22024     Document Type: Letter

References (30)

1. Martinelli I, De Stefano V. Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review. Thromb Haemost 2010; 103: 1136-1144.
2. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23: 411-418.
3. Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000; 31: 587-591.
4. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41: 603-608.
5. Murad SD, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167-175.
6. Anger BR, Seifried E, Scheppach J, Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 1989; 67: 818-825.
7. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999; 78: 539-543.
8. Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential thrombocythemia: Prevalence, clinical correlates, and prognostic implications. Eur J Haematol 2006; 77: 327-333.
9. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
10. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
11. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61.
12. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.
13. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases. Blood 2008; 111: 4922-4929.
14. Fiorini A, Chiusolo P, Rossi E, et al. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. Am J Hematol 2009; 84: 126-127.
15. Tondeur S, Boutruche S, Biron-Andréani C, Schved J-F. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thromb Haemost 2009; 101: 787-789.
16. Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: A meta-analysis. Blood 2009; 113: 5617-5623.
17. Sozer S, Fiel MI, Schiano T, et al. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009; 113: 5246-5249.
18. Za T, Fiorini A, Rossi E, et al. Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. Br J Haematol 2009; 144: 965-967.
19. Koopman K, Mulder AB, De Keyser J, et al. JAK2-V617F mutation in cerebral venous thrombosis. J Thromb Haemost 2009; 7: 1039-40.
20. De Stefano V, Rossi E, Za T, et al. The JAK2 V617F mutation in patients with cerebral venous thrombosis: A rebuttal. Thromb Haemost 2008; 99: 1121.
21. Godeneche G, Gaillard N, Roy L, et al. JAK2 V617F mutation associated with cerebral venous thrombosis: A report of five cases. Cerebrovasc Dis 2010; 29: 206-209.
22. De Stefano V, Za T, Rossi E, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica 2009; 94: 733-737.
23. Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential hrombocythemia: Measuring the uncertain. Haematologica 2008; 93: 1412-1414.
24. Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index ? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33: 67-73.
25. Lussana F, Caberlon S, Pagani C, et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review. Thromb Res 2009; 124: 284-294.
26. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129: 553-560.
27. Tefferi A. Essential thrombocythemia: Scientific advances and current practice. Curr Opin Hematol 2006; 13: 93-98.
28. WHO classification of the chronic myeloproliferative diseases (CMPD) polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia and CMPD unclassifiable. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors.World Health Organization Classification of Tumours, Vol. 3. Pathology and genetics of Tumours of haematopoietic and lymphoid tissues. Lyon, France, IARC Press; 2001. pp 31-42.
29. Gruppo Italiano Studio Policitemia. Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664.
30. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: An unrecognized diagnosis. Am J Med 1997; 102: 14-20.